诺和诺德公司下调业绩指引并CEO辞职被视为"双重意外"：BMO

英为财情

2025/07/29

Investing.com -- 据BMO Capital Markets分析师Evan David Seigerman表示，诺和诺德公司下调业绩指引和CEO辞职代表了一个"双重意外"。在给客户的一份报告中，保持对这家丹麦制药商"市场表现"评级的Seigerman指出了影响公司业绩的"多方面阻力"。该分析师强调，诺和诺德公司在美国市场的关键产品——减肥药Wegovy和糖尿病药物Ozempic的...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555054395"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555054395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555054395?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-29 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555054395","market":"sh","top_or_hot":-1,"title":"诺和诺德公司下调业绩指引并CEO辞职被视为\"双重意外\"：BMO","media":"英为财情","content":"<div>\n<p>Investing.com -- 据BMO Capital Markets分析师Evan David Seigerman表示，诺和诺德公司下调业绩指引和CEO辞职代表了一个\"双重意外\"。\n在给客户的一份报告中，保持对这家丹麦制药商\"市场表现\"评级的Seigerman指出了影响公司业绩的\"多方面阻力\"。\n该分析师强调，诺和诺德公司在美国市场的关键产品——减肥药Wegovy和糖尿病药物Ozempic的...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2907739\">网页链接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德公司下调业绩指引并CEO辞职被视为\"双重意外\"：BMO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德公司下调业绩指引并CEO辞职被视为\"双重意外\"：BMO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-29 21:17 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cn.investing.com/news/stock-market-news/article-93CH-2907739><strong>英为财情</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing.com -- 据BMO Capital Markets分析师Evan David Seigerman表示，诺和诺德公司下调业绩指引和CEO辞职代表了一个\"双重意外\"。\n在给客户的一份报告中，保持对这家丹麦制药商\"市场表现\"评级的Seigerman指出了影响公司业绩的\"多方面阻力\"。\n该分析师强调，诺和诺德公司在美国市场的关键产品——减肥药Wegovy和糖尿病药物Ozempic的...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2907739\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2907739","article_id":"2555054395","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2907739","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2555054395","pubTimestamp":1753795020,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- 据BMO Capital Markets分析师Evan David Seigerman表示，诺和诺德公司下调业绩指引和CEO辞职代表了一个\"双重意外\"。在给客户的一份报告中，保持对这家丹麦制药商\"市场表现\"评级的Seigerman指出了影响公司业绩的\"多方面阻力\"。该分析师强调，诺和诺德公司在美国市场的关键产品——减肥药Wegovy和糖尿病药物Ozempic的增长预期降低。尽管面临这些挑战，Seigerman对公司的领导层变更持较为积极的态度，表示\"一位非丹麦CEO的全球视角可能会为陷入困境的战略注入新活力并重新聚焦。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","NVO":"诺和诺德","BK4599":"减肥药","BK4585":"ETF&股票定投概念","BK4007":"制药","BK4207":"综合性银行","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BMO":"蒙特利尔银行","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"Novo Nordisk cuts guidance and CEO resignation seen as'double surprise ': BMO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMO":1,"NVO":1},"content_text":"Investing.com -- 据BMO Capital Markets分析师Evan David Seigerman表示，诺和诺德公司下调业绩指引和CEO辞职代表了一个\"双重意外\"。\n在给客户的一份报告中，保持对这家丹麦制药商\"市场表现\"评级的Seigerman指出了影响公司业绩的\"多方面阻力\"。\n该分析师强调，诺和诺德公司在美国市场的关键产品——减肥药Wegovy和糖尿病药物Ozempic的增长预期降低。国际市场对Wegovy的渗透率也低于预期。\nSeigerman写道：\"Wegovy销售预期下降主要受到美国市场持续/高于预期的复合影响以及在竞争环境下市场扩张速度低于预期的影响\"，暗示礼来的tirzepatide可能是造成竞争压力的原因。\nOzempic在美国市场的表现不佳\"因竞争而加剧\"，公司的胰高血糖素样肽-1(incretin)产品组合面临的压力超过管理层最初的预期。\n尽管面临这些挑战，Seigerman对公司的领导层变更持较为积极的态度，表示\"一位非丹麦CEO的全球视角可能会为陷入困境的战略注入新活力并重新聚焦。\"\n\n本文由人工智能协助翻译。更多信息，请参见我们的使用条款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"executive,shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}